Citations (42)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Atul Tiwari. (2008) Elocalcitol (BXL-628): a novel, investigational therapy for the therapeutic management of benign prostatic hyperplasia. Expert Opinion on Investigational Drugs 17:5, pages 819-824.
Read now
Read now
Atul Tiwari. (2007) Advances in the development of hormonal modulators for the treatment of benign prostatic hyperplasia. Expert Opinion on Investigational Drugs 16:9, pages 1425-1439.
Read now
Read now
Atul Tiwari & Krishna S Naruganahalli. (2006) Current and emerging investigational medical therapies for the treatment of overactive bladder. Expert Opinion on Investigational Drugs 15:9, pages 1017-1037.
Read now
Read now
PKS Sarma, Atul Tiwari, Atul Kondaskar & Ian A Cliffe. (2006) Peptidomimetic GnRH receptor antagonists for the treatment of reproductive and proliferative diseases. Expert Opinion on Therapeutic Patents 16:6, pages 733-751.
Read now
Read now
Articles from other publishers (38)
Deusdedit Tusubira, Jonasi Munezero, Peter Chinedu Agu, Clement Olusoji Ajayi, Joseph Oloro, Nathiim Namale, Frank Ssedyabane, Caroline Kiwanuka Nakiguli, Abayomi E. Adegboyega & Patrick Maduabuchi Aja. (2023) In-vivo and in-silico studies revealed the molecular mechanisms of Colocasia esculenta phenolics as novel chemotherapy against benign prostatic hyperplasia via inhibition of 5α-reductase and α1-adrenoceptor. In Silico Pharmacology 11:1.
Crossref
Crossref
Akansha Sharma, Priyanka Rana, Poonam Arora, Tanzeer Kaur & Neelima Dhingra. (2022) Synthesis, Characterization and Evaluation of 5α, 6β-Dihalo Androsterone
Derivatives as 5α-Reductase Inhibitors. Current Enzyme Inhibition 18:3, pages 180-193.
Crossref
Crossref
Chu-Wen Fang, Chun-Hao Chen, Kun-Hung Shen, Wen-Chi Yang, Chih-Hsin Muo & Shih-Chi Wu. (2020) Increased risk of subsequent benign prostatic hyperplasia in non-Helicobacter pylori-infected peptic ulcer patients: a population-based cohort study. Scientific Reports 10:1.
Crossref
Crossref
Ceyda Tuba Sengel-Turk, Mehmet Eray Alcigir, Okan Ekim, Filiz Bakar-Ates & Canan Hascicek. (2020) Clinicopathological and immunohistochemical evaluation of lonidamine-entrapped lipid–polymer hybrid nanoparticles in treatment of benign prostatic hyperplasia: An experimental rat model. European Journal of Pharmaceutics and Biopharmaceutics 157, pages 211-220.
Crossref
Crossref
Wang Xi, Qiaogen Zou & Pingkai Ouyang. (2019) Pharmacokinetics of cligosiban in dog plasma after oral administration by liquid chromatography electrospray ionization tandem mass spectrometry. Biomedical Chromatography 33:10.
Crossref
Crossref
Xueliang Yue, Lingpan Lu, Hongshan Liu & Huanzhou Xue. (2019) Pharmacokinetics, bioavailability and metabolism of cligosiban, an antagonist of oxytocin receptor, in rat by liquid chromatography hyphenated with electrospray ionization tandem mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis 164, pages 725-733.
Crossref
Crossref
Neelima Dhingra. (2018) In silico Identification of potential 5α‒reductase inhibitors for prostatic diseases: QSAR modelling, molecular docking, and pre ADME predictions. MOJ Drug Design Development & Therapy 2:3.
Crossref
Crossref
William B. Coleman. 2018. Molecular Pathology. Molecular Pathology
71
97
.
Kejing Lao, Jie Sun, Chong Wang, Weiting Lyu, Boshen Zhou, Ruheng Zhao, Qian Xu, Qidong You & Hua Xiang. (2017) Design, synthesis and biological evaluation of novel androst-3,5-diene-3-carboxylic acid derivatives as inhibitors of 5α-reductase type 1 and 2. Steroids 124, pages 29-34.
Crossref
Crossref
Caroline M. Moore & Mark Emberton. 2017. Imaging and Focal Therapy of Early Prostate Cancer. Imaging and Focal Therapy of Early Prostate Cancer
293
306
.
Eunjin JeonKyung-Sook ChungHyo-Jin An. (2016)
Anti-proliferation effects of
Cistanches salsa
on the progression of benign prostatic hyperplasia
. Canadian Journal of Physiology and Pharmacology 94:1, pages 104-111.
Crossref
Crossref
Liya Liu, Yun Wan, Aling Shen, Jinyan Zhao, Jiumao Lin, Xiaoyong Zhong, Yuchen Zhang & Zhenfeng Hong. (2015) miRNA Regulation Network Analysis in Qianliening Capsule Treatment of Benign Prostatic Hyperplasia. Evidence-Based Complementary and Alternative Medicine 2015, pages 1-9.
Crossref
Crossref
Simone Chevalier, Fabio L. Cury, Eleonora Scarlata, Ehab El-Zayat, Lucie Hamel, Joice Rocha, Fatima Z. Zouanat, Sabri Moussa, Avigdor Scherz, Mostafa Elhilali & Maurice Anidjar. (2013) Endoscopic Vascular Targeted Photodynamic Therapy with the Photosensitizer WST11 for Benign Prostatic Hyperplasia in the Preclinical Dog Model. The Journal of Urology 190:5, pages 1946-1953.
Crossref
Crossref
Hui-Wen Chiu, Mei-Huei Chen, Wen-Hung Fang, Ching-Ming Hung, Yen-Lin Chen, Ming-Der Wu, Gwo-Fang Yuan, Ming-Jiuan Wu & Ying-Jan Wang. (2013) Preventive Effects of Monascus on Androgen-Related Diseases: Androgenetic Alopecia, Benign Prostatic Hyperplasia, and Prostate Cancer. Journal of Agricultural and Food Chemistry 61:18, pages 4379-4386.
Crossref
Crossref
Alan D. Borthwick & John Liddle. 2013. Protein-Protein Interactions in Drug Discovery. Protein-Protein Interactions in Drug Discovery
225
256
.
Caroline M. Moore & Mark Emberton. 2013. Imaging and Focal Therapy of Early Prostate Cancer. Imaging and Focal Therapy of Early Prostate Cancer
283
295
.
Saurabh Aggarwal, Suresh Thareja, T.R. Bhardwaj, J?rg Haupenthal, R.W. Hartmann & Manoj Kumar. (2012) Synthesis and biological evaluation of novel unsaturated carboxysteroids as?human 5?-reductase inhibitors: A legitimate approach. European Journal of Medicinal Chemistry 54, pages 728-739.
Crossref
Crossref
Liang-Ming Lee, Chih-Cheng Lu, Hsien-Hui Chung & Juei-Tang Cheng. (2012) Prostatic Relaxation Induced by Loperamide Is Reduced in Spontaneously Hypertensive Rats. The Scientific World Journal 2012, pages 1-7.
Crossref
Crossref
Jeroen C. Verheijen, David J. Richard & Arie Zask. 2011. Kinase Drug Discovery. Kinase Drug Discovery
161
217
.
Lucas P. Nacusi & Donald J. Tindall. (2011) Targeting 5α-reductase for prostate cancer prevention and treatment. Nature Reviews Urology 8:7, pages 378-384.
Crossref
Crossref
Pedro A.V. Reis de Souza, Antonio PalumboJrJr, Leandro M. Alves, Valéria Pereira de Souza, Lúcio M. Cabral, Patrícia D. Fernandes, Christina M. Takiya, Fábio S. Menezes & Luiz E. Nasciutti. (2011) Effects of a nanocomposite containing Orbignya speciosa lipophilic extract on Benign Prostatic Hyperplasia. Journal of Ethnopharmacology 135:1, pages 135-146.
Crossref
Crossref
CHIH-CHENG LU, HSIEN-HUI CHUNG & JUEI-TANG CHENG. (2011) Prostatic relaxation induced by loperamide is mediated through activation of opioid μ-2 receptors in vitro. Experimental and Therapeutic Medicine 2:2, pages 281-285.
Crossref
Crossref
Alan D. Borthwick. (2010) Oral Oxytocin Antagonists. Journal of Medicinal Chemistry 53:18, pages 6525-6538.
Crossref
Crossref
Xin Zhao, Mu Yuan, Biyun Huang, Hong Ji & Liu Zhu. (2010) Ligand-based pharmacophore model of N-Aryl and N-Heteroaryl piperazine ?1A-adrenoceptors antagonists using GALAHAD. Journal of Molecular Graphics and Modelling 29:2, pages 126-136.
Crossref
Crossref
Alan Brown, Dave Ellis, Olga Wallace & Michael Ralph. (2010) Identification of amide bioisosteres of triazole Oxytocin antagonists. Bioorganic & Medicinal Chemistry Letters 20:7, pages 2224-2228.
Crossref
Crossref
Alan Brown, Dave Ellis, Olga Wallace & Michael Ralph. (2010) Identification of a urea bioisostere of a triazole oxytocin antagonist. Bioorganic & Medicinal Chemistry Letters 20:6, pages 1851-1853.
Crossref
Crossref
Alan Brown, T. Bruce Brown, Andrew Calabrese, Dave Ellis, Nicholas Puhalo, Michael Ralph & Lesa Watson. (2010) Triazole oxytocin antagonists: Identification of an aryloxyazetidine replacement for a biaryl substituent. Bioorganic & Medicinal Chemistry Letters 20:2, pages 516-520.
Crossref
Crossref
Osamu Yamaguchi, Ken Aikawa, Keiichi Shishido & Masanori Nomiya. (2009) Place of overactive bladder in male lower urinary tract symptoms. World Journal of Urology 27:6, pages 723-728.
Crossref
Crossref
Alexander Roosen, Ben T. Blake‐James, Daniel Wood & Christopher H. Fry. (2009) Clinical and experimental aspects of Adreno‐muscarinic synergy in the bladder base and prostate. Neurourology and Urodynamics 28:8, pages 938-943.
Crossref
Crossref
Alan Brown, Dave Ellis, David Pearce, Michael Ralph & Nunzio Sciammetta. (2009) Aryloxypyrazines as highly selective antagonists of Oxytocin. Bioorganic & Medicinal Chemistry Letters 19:10, pages 2634-2636.
Crossref
Crossref
Kamna Nanda, Krishna S. Naruganahalli, Suman Gupta, Shivani Malhotra, Atul Tiwari, Laxminarayan G. Hegde, Sanjay Jain, Neelima Sinha, Jung B. Gupta, Anita Chugh, Nitya Anand & Abhijit Ray. (2009) RBx 6198: A novel α1-adrenoceptor antagonist for the treatment of benign prostatic hyperplasia. European Journal of Pharmacology 607:1-3, pages 213-219.
Crossref
Crossref
Paloma Alonso-MagdalenaClemens BrössnerAngelika Reiner, Guojun Cheng, Nobuhiro Sugiyama, Margaret Warner & Jan-Åke Gustafsson. (2009) A role for epithelial-mesenchymal transition in the etiology of benign prostatic hyperplasia. Proceedings of the National Academy of Sciences 106:8, pages 2859-2863.
Crossref
Crossref
William B. Coleman & Tara C. Rubinas. 2009. Molecular Pathology. Molecular Pathology
63
86
.
Craig V. Comiter. 2009. Continence. Continence
393
409
.
Alan Brown, Lindsay Brown, T. Bruce Brown, Andrew Calabrese, Dave Ellis, Nicholas Puhalo, Chris R. Smith, Olga Wallace & Lesa Watson. (2008) Triazole oxytocin antagonists: Identification of aryl ether replacements for a biaryl substituent. Bioorganic & Medicinal Chemistry Letters 18:19, pages 5242-5244.
Crossref
Crossref
Alan Brown, Lindsay Brown, Dave Ellis, Nicholas Puhalo, Chris R. Smith, Olga Wallace & Lesa Watson. (2008) Design and optimization of potent, selective antagonists of Oxytocin. Bioorganic & Medicinal Chemistry Letters 18:15, pages 4278-4281.
Crossref
Crossref
W.M. Kwiatek, A. Banaś, K. Banaś, G. Cinque, G. Dyduch, G. Falkenberg, A. Kisiel, A. Marcelli & M. Podgórczyk. (2007) Micro and bulk analysis of prostate tissues classified as hyperplasia. Spectrochimica Acta Part B: Atomic Spectroscopy 62:6-7, pages 707-710.
Crossref
Crossref
Christopher R. Chapple & Claus G. Roehrborn. (2006) A Shifted Paradigm for the Further Understanding, Evaluation, and Treatment of Lower Urinary Tract Symptoms in Men: Focus on the Bladder. European Urology 49:4, pages 651-659.
Crossref
Crossref